Loading organizations...
§ Private Profile · Abingdon, UK
Syntaxin is a technology company.
Syntaxin engineers bacterial toxins to develop innovative drug therapies designed to inhibit abnormal cell secretion, a fundamental process implicated in numerous pathologies. The company's unique platform focuses on creating novel compounds to address a range of neurological, inflammatory, and endocrine diseases, leveraging precise biological mechanisms to modulate cellular function at a molecular level. Their approach offers a targeted strategy for conditions often lacking effective treatments.
The company emerged in November 2005 as a spin-out from the UK Health Protection Agency, with Dr. Keith Foster, then Chief Scientific Officer, among its founders. This origin provided Syntaxin with a deep institutional understanding of bacterial toxins and their potential therapeutic applications. The foundational insight revolved around harnessing these potent biological agents, traditionally associated with disease, and re-engineering them into highly specific pharmacological tools.
Syntaxin's product pipeline is intended for patients confronting chronic and debilitating neurological, inflammatory, and endocrine conditions. The company's vision centers on pioneering a new class of targeted therapeutics that significantly improve patient outcomes by precisely controlling cellular processes. They aim to establish their engineered bacterial toxins as a foundational technology for treating complex diseases with high unmet medical need.
Syntaxin has raised $71.0M across 3 funding rounds.
Syntaxin has raised $71.0M in total across 3 funding rounds.
Syntaxin was a UK-based biopharmaceutical company specializing in the engineering and development of bacterial-based protein therapeutics, particularly recombinant botulinum toxin (BoNT) technologies, for treating neurological, inflammatory, and endocrine diseases.[1][2][3] It built innovative compounds using its proprietary TSI (Targeted Secretion Inhibitor) platform, which retargeted botulinum toxin molecules to expand therapeutic applications beyond traditional uses, serving patients with conditions like muscle spasticity, pain, and inflammation.[1][4] The company solved key challenges in toxin-based therapies by enabling precise molecular design for safer, more targeted treatments, but its independent growth was cut short by acquisition in 2013, limiting public visibility on later momentum.[1]
Syntaxin was formed in 2005 as a venture capital-backed spin-out from the UK Health Protection Agency (HPA), leveraging 18 years of research in bacterial toxin engineering conducted at HPA's Porton Down facility.[1][6] This origin stemmed from decades of foundational work in botulinum toxin science, positioning Syntaxin as a leader in recombinant BoNT development with a productive R&D team and strong IP portfolio of 75 granted patents and over 130 pending.[1] Early traction included a 2010 strategic partnership with Ipsen for discovering new recombinant BoNT compounds, culminating in Ipsen's full acquisition in 2011 (finalized July 15, 2013) for approximately $207 million, which integrated Syntaxin's expertise into Ipsen's patient-centric R&D strategy focused on innovative new molecular entities.[1][4]
Syntaxin rode the wave of advanced biologics and precision medicine trends in the early 2010s, capitalizing on growing demand for engineered toxins amid rising neurological and pain management needs.[1][2] Its timing aligned with pharma's shift toward open innovation and platform technologies, as seen in Ipsen's acquisition to bolster its toxin R&D leadership and two core platforms (toxins and peptides).[1] Market forces like patent expirations on legacy BoNTs and regulatory interest in safer alternatives favored Syntaxin's disruptive IP, influencing the ecosystem by enhancing Ipsen's pipeline and validating spin-out models from public research agencies.[1][4] Post-acquisition, its tech contributed to Ipsen's science-driven, patient-centric strategy, indirectly shaping botulinum-based therapeutics in aesthetics, neurology, and beyond.
Post-2013 acquisition, Syntaxin operates as an integrated part of Ipsen's R&D, with its TSI platform likely fueling ongoing BoNT innovations amid trends like targeted biologics, AI-driven drug design, and expanded indications for neuromodulators.[1] Rising demand for non-opioid pain therapies and endocrine treatments positions this legacy tech for growth, potentially evolving through Ipsen's global partnerships and life-cycle management initiatives. As biotech consolidates, Syntaxin's influence endures via Ipsen's reinforced leadership, tying back to its spin-out roots in pioneering recombinant toxins for transformative patient outcomes.
Syntaxin has raised $71.0M in total across 3 funding rounds.
Syntaxin's investors include Abingworth, Red Tree Venture Capital, Ipsen, Johnson & Johnson Innovation, LSP, Lundbeckfond Ventures, Quest Ventures, Seventure Partners, SR One, René Kuijten, EQT Life Sciences, Zeev Zehavi.
Syntaxin has raised $71.0M across 3 funding rounds. Most recently, it raised $29.0M Series C in November 2010.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2010 | $29M Series C | — | Abingworth, RED Tree Venture Capital, Ipsen, Johnson & Johnson Innovation, LSP, Lundbeckfond Ventures, Quest Ventures, Seventure Partners, SR ONE | Announced |
| Oct 1, 2007 | $32M Series B | SR ONE, René Kuijten | Abingworth, EQT Life Sciences, RED Tree Venture Capital, Zeev Zehavi, Quest For Growth | Announced |
| Nov 1, 2005 | $10M Series A | — | Abingworth, RED Tree Venture Capital | Announced |